NCT04676477
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 18 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 63 words Show 4 more changesShow less
- Study completion pushed from Apr 30, 2027 to Dec 14, 2027
- Secondary endpoints: details revised at 3 of 13 entries
- Collaborators: details revised at 1 of 2 entries
- Study description expanded, about 2 words
- Notable Eligibility criteria revised
- Enrollment target: estimated 280 to confirmed 246
- Primary completion date changed from estimate of Jun 1, 2025 to Jan 31, 2025
- Study completion date: Feb 1, 2026 to Apr 30, 2027
- Notable Eligibility criteria revised
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 31 of 31 sites
- Notable Eligibility criteria revisedv16
- Notable Eligibility criteria expanded, about 64 words
- Secondary endpoints: details revised at 3 of 13 entries
- Site details revised at 1 of 31 sites
- Collaborators expanded, about 6 words
Show 12 earlier versionsHide 12 earlier versions
- Minor Site details revised at 1 of 31 sitesv14
- Minor Site details revised at 4 of 31 sitesv13
- Minor Primary completion date: Jun 2025 to Jun 1, 2025
- Study completion date: Feb 2026 to Feb 1, 2026
- Site details revised at 5 of 31 sites
- Minor Study sites: 16 to 31v11
Notable Primary completion date: Jan 2024 to Jun 2025v10 Show 10 more changesShow less
- Eligibility criteria expanded, about 139 words
- Primary endpoints: 3 to 2
- Enrollment target: 252 to 280
- Study sites: 15 to 16
- Study completion date: Jan 2024 to Feb 2026
- Interventions: Osimertinib (Drug), Osimertinib (Drug), Osimertinib (Drug), Patritumab deruxtecan (Drug), Patritumab deruxtecan (Drug), Patritumab… to HER3-DXd (Drug), HER3-DXd (Drug), HER3-DXd (Drug), HER3-DXd (Drug), Osimertinib (Drug), Osimertinib (Drug), Osimertinib (Drug)
- Secondary endpoints: 12 to 13
- Study arms: 4 to 6
- Study description shortened, about 1 word
- Study title expanded, about 2 words
- Minor Study sites: 14 to 15v9
- Minor Study sites: 11 to 14v8
- Minor Study sites: 7 to 11v7
- Notable Eligibility criteria expanded, about 27 words
- Site details revised at 1 of 7 sites
- Minor Study sites: 5 to 7v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 2021 to Jun 11, 2021
- Site details revised at 5 of 5 sites
- Notable Start date: Jan 2021 to Apr 2021
- Eligibility criteria expanded, about 76 words
- Study sites revised (5)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Participants in the Dose Escalation phase will receive HER3-DXd IV Q3W + osimertinib PO once daily. The dose of HER3-DXd in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.
Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd + osimertinib at the RCD
Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W
If the RCD includes an osimertinib dose of 80 mg PO once daily, then participants will receive treatment with HER3-DXd and osimertinib at the RCD
Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.
Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 4.8 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.
Drugs: HER3-DXd, Osimertinib
Sites
31 sites in 4 countries
United States 13, Japan 10, South Korea 4, Taiwan 4